DUal Antithrombotic therapy for acute ischemic stroke with symptomatic Large-artery steno-occlusion and Atrial Fibrillation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0011777

Enrollment

770

Registered

2026-03-25

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The intervention arm receives apixaban 5 mg twice daily (or 2.5 mg twice daily if dose-reduction criteria are met) plus antiplatelet therapy (aspirin 100–300 mg/day or clopidogrel 75 mg/day, wi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: · Acute ischemic stroke within 48 hours of onset or lesion-positive transient ischemic attack · Adults aged 19 years or older · History of or newly diagnosed non-valvular atrial fibrillation · Imaging-confirmed relevant atherosclerotic large-artery steno-occlusion/occlusion (rLASO) related to the index infarct lesion · Eligible to start anticoagulation within 4 days of onset (within 7 days in major stroke) · Signed informed consent within 7 days of admission

Exclusion criteria

Exclusion criteria: · Contraindications to direct oral anticoagulants (e.g., mechanical valve or valvular atrial fibrillation) · Clinically mandated use of antiplatelet therapy during the study period · Patients for whom study medication is considered inappropriate due to bleeding risk or clinical status at the investigator’s discretion · Hypersensitivity to apixaban, aspirin, or clopidogrel · Any other condition judged by the treating investigator to preclude participation

Design outcomes

Primary

Measure	Time frame
A composite of stroke, myocardial infarction, or death from any cause within 1 year after randomization.	—

Secondary

Measure	Time frame
All stroke (ischemic and hemorrhagic);Ischemic stroke or transient cerebral ischemia;Myocardial infarction;All-cause death;Vascular death;Ischemic stroke in the territory of rLASO;Composite vascular events (stroke, myocardial infarction, or all-cause death);Recurrent stroke;Major bleeding (BARC Type 3A, 3B, 3C, 4, 5A, 5B);Symptomatic intracerebral hemorrhage;Intracranial hemorrhage	—

Countries

Korea, Republic of

Contacts

Public ContactHEEJOON BAE

Seoul National University Bundang Hospital

braindocbae@gmail.com+82-31-787-7467

Outcome results